Patients & Caregivers

Don’t get lost in the dark. Know where you are on your patient journey.

CELLSEARCH® is a liquid biopsy test that helps inform your doctor’s clinical decisions by providing a count of tumor cells circulating in your bloodstream.

What is a Circulating Tumor Cell (CTC) liquid biopsy?

A liquid biopsy is simply a test performed on a sample of blood taken from a patient.

The CELLSEARCH® test looks for cancer cells that are circulating in the patient’s bloodstream. By counting (aka, enumerating) these circulating tumor cells, doctors may be able to provide an assessment or detect changes in a patient’s disease at any time.

How will my doctor use CELLSEARCH® to monitor my disease?

The CELLSEARCH® test can provide information to your doctor in a non-invasive, fast, and reliable manner that can help inform their decisions on your course of treatment and disease management.

Is the test covered by my insurance?

The test is currently being offered to eligible physicians to provide to their patients throughout the duration of the Physician Experience Program. Please speak with your doctor to determine if they meet the eligibility criteria to enroll in the program and receive tests on your behalf. 

In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. Patients or their caregivers can apply for financial assistance at any point during the testing process. A financial assistance application can be obtained by contacting our customer support team at 1-877-837-4339  (M-F 8:30AM – 5:00PM EST).


Tests are currently available for the following diseases:

  • Certain Metastatic Solid Tumors
  • Clinically Relevant Biomarkers (eg, PD-L1, HER2)
  • Multiple Myeloma

Ask your doctor about CELLSEARCH®, to find out if this test is right for you.

The performance, characteristics, safety, and effectiveness of the PD-L1 Biomarker with Enumeration, CMMC Enumeration, HER2 Biomarker with Enumeration, and CMC Biomarker with Enumeration lab-developed tests have not been cleared or approved by the FDA.

The CELLSEARCH® Circulating Tumor Cell (CTC) test is FDA-cleared for detecting CTCs in cancer patients with metastatic breast, prostate*, or colorectal cancer.

*Metastatic prostate cancer patients were defined as having two consecutive increases in the serum marker prostate-specific antigen above a reference level, despite standard hormonal management. These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer.